deltatrials
Completed PHASE3 NCT00432276

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg Versus Dose Titration From 30 mg to 45 mg of Pioglitazone HCl (ACTOS®) in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Control on a Combination of Metformin and 30 mg of Pioglitazone HCl Therapy

Sponsor: Takeda

Conditions Diabetes Mellitus
Interventions Alogliptin Metformin Pioglitazone Placebo
Updated 7 times since 2017 Last updated: Apr 1, 2013 Started: Jan 31, 2007 Primary completion: May 31, 2009 Completion: Jun 30, 2009

This PHASE3 trial investigates Diabetes Mellitus and is currently completed. Takeda leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Takeda
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aliquippa, United States, Altoona, United States, Arlington, United States, Asheboro, United States, Ashland, United States, Austin, United States, Bay City, United States, Birmingham, United States, Bismarck, United States, Blackwood, United States and 76 more location s